RT info:eu-repo/semantics/article
T1 Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients
A1 Aydillo, Teresa
A1 Escalera, Alba
A1 Strohmeier, Shirin
A1 Aslam, Sadaf
A1 Sánchez Céspedes, Javier
A1 Ayllón Barasoain, Juan
A1 Roca Oporto, Cristina
A1 Pérez Romero, Pilar
A1 Montejo, Miguel
A1 Gavalda, Joan
A1 Muñoz, Patricia
A1 López Medrano, Francisco
A1 Carratala, Jordi
A1 Krammer, Florian
A1 García Sastre, Adolfo
A1 Cordero, Elisa
K1 Influenza antibodies
K1 Correlates of protection
K1 Transplant patients
K1 Viral pneumonia
K1 Medicina
K1 Medicine
K1 Microbiología
K1 Microbiology
K1 Enfermedades infecciosas
K1 Communicable diseases
AB Hemagglutination-inhibitory antibodies are usually highly strain specific with little effect on infection with drifted or shifted strains. The significance of broadly cross-reactive non-HAI anti-influenza antibodies against conserved domains of virus glycoproteins, such as the hemagglutinin (HA) stalk, is of great interest. We characterize a cohort of 40 H1N1pmd09 influenza-infected patients and identify lower respiratory symptoms (LRSs) as a predictor for development of pneumonia. A binomial logistic regression of log10 pre-existing antibody values shows that the probability of LRS occurrence decreased with increased anti-HA full-length and stalk antibody ELISA titers. However, a multilevel logistic regression model adjusted by other potential serocorrelates demonstrates that only antibodies directed against the stalk of HA correlate with protection from lower respiratory infection, limiting disease progression. Our predictive model indicates that a threshold of protective immunity based on broadly cross-reactive HA stalk antibodies could be feasible.
PB Cell Press
SN 2666-3791
YR 2020
FD 2020
LK http://hdl.handle.net/10259/7993
UL http://hdl.handle.net/10259/7993
LA eng
NO This work was supported by the Programa de Investigación sobre gripe A/H1N1, Instituto de Salud Carlos III, Ministerio. de Ciencia e Innovación (GR09/0041); the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, co-financed by the European Development Regional Fund “A way to Achieve Europe” ERDF; the Spanish Network for Research in Infectious Diseases (REIPI RD06/0008 to E.C.); NIAID grants P01AI097092 and U19AI135972; CRIP (Center for Research on Influenza Pathogenesis), an NIAID-funded Center of Excellence on Influenza Research and Surveillance (CEIRS; contract HHSN272201400008C); and SEM-CIVIC, an NIAID-funded Collaborative Influenza Vaccine Innovation Center (contract 75N93019C00051 to A.G.-S. and F.K.).
DS Repositorio Institucional de la Universidad de Burgos
RD 10-may-2024